Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Melanoma × romiplostim × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocytopenia 4 Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Solid Tumor 1 Ovarian Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Hodgkin Disease 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Ipilimumab 93 Nivolumab 88 pembrolizumab 81 aldesleukin 65 Cyclophosphamide 42 Interleukin-2 39 trametinib 29 Temozolomide 28 Dacarbazine 28 fludarabine phosphate 27 dabrafenib 27 incomplete Freund's adjuvant 25 Vemurafenib 24 Bevacizumab 24 sargramostim 22 fludarabine 22 Radiosurgery 20 binimetinib 18 encorafenib 17 Paclitaxel 17 cobimetinib 15 Carboplatin 15 atezolizumab 14 Radiotherapy 14 Sorafenib 12 montanide ISA 51 11 CTLA-4 Antigen 11 Biopsy 11 talimogene laherparepvec 10 MART-1 Antigen 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡